Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen

详细信息    查看全文

• 作者：Yuhua Li ; Weijun Zhou ; Jingwen Du ; Chunjun Jiang…
• 关键词：Eps8 ; HLA ; A2.1 ; Immunotherapy ; Cytotoxic T cell (CTL) ; Modified epitope
• 刊名：Cancer Immunology, Immunotherapy
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：64
• 期：2
• 页码：259-269
• 全文大小：752 KB
• 参考文献：1. Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4(5):401-11 CrossRef
  2. Mocellin S, Semenzato G, Mandruzzato S, Riccardo RC (2004) Part II: vaccines for haematological malignant disorders. Lancet Oncol 5(12):727-37 CrossRef
  3. Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P (2013) Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun 13:15
  4. Anderson LJ, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR (2011) Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma. Cancer Immunol Immunother 60(7):985-97 CrossRef
  5. Sun Z, Lethe B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P (2006) A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunol Immunother 55(6):644-52 CrossRef
  6. Matsuzaki J, Qian F, Luescher I, Lele S, Ritter G, Shrikant PA, Gnjatic S, Old LJ, Odunsi K (2008) Recognition of naturally processed and ovarian cancer reactive CD8?+?T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1. Cancer Immunol Immunother 57(8):1185-195 CrossRef
  7. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C (2009) A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113(26):6541-548 CrossRef
  8. Emens LA (2012) Re-purposing cancer therapeutics for breast cancer immunotherapy. Cancer Immunol Immunother 61(8):1299-305 CrossRef
  9. Parmiani G, Russo V, Maccalli C, Parolini D, Rizzo N, Maio M. (2014) Peptide-based vaccines for cancer therapy. Hum Vaccin Immunother, 10(11). Advance online publication. doi:10.4161/hv.29418
  10. Li YH, Xue TY, He YZ, Du JW (2013) Novel oncoprotein EPS8: a new target for anticancer therapy. Future Oncol 9:1587-594 CrossRef
  11. Fazioli F, Minichiello L, Matoska V, Castagnino P, Miki T, Wong WT, Di Fiore PP (1993) Eps8, a substrate for the epidermal growth factor receptor kinase, enhances EGF-dependent mitogenic signals. EMBO J 12(10):3799-808
  12. Scita G, Nordstrom J, Carbone R, Tenca P, Giardina G, Gutkind S, Bjarnegard M, Betsholtz C, Di Fiore PP (1999) EPS8 and E3B1 transduce signals from Ras to Rac. Nature 401(6750):290-93 CrossRef
  13. Scita G, Tenca P, Areces LB, Tocchetti A, Frittoli E, Giardina G, Ponzanelli I, Sini P, Innocenti M, Di Fiore PP (2001) An effector region in Eps8 is responsible for the activation of the Rac-specific GEF activity of Sos-1 and for the proper localization of the Rac-based actin-polymerizing machine. J Cell Biol 154(5):1031-044 CrossRef
  14. Disanza A, Carlier MF, Stradal TE, Didry D, Frittoli E, Confalonieri S, Croce A, Wehland J, Di Fiore PP, Scita G (2004) Eps8 controls actin-based motility by capping the barbed ends of actin filaments. Nat Cell Biol 6(12):1180-188 CrossRef
  15. Shieh DC, Lin DT, Yang BS, Kuan HL, Kao KJ (1996) High frequency of HLA-A*0207 subtype in Chinese population. Transfusion 36(9):818-21 CrossRef
  16. Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A (1993) Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74(5):929-37 CrossRef
  17. Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Immunology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0851

文摘

The ideal tumor antigen for the development of a cancer immunotherapy is one that is expressed only in tumor cells. The epidermal growth factor receptor pathway substrate 8 gene (Eps8) might be an effective antigen for cancer immunotherapy as it is overexpressed in a variety of cancer cells but not in normal tissues. In this study, the potential utility of an Eps8-derived immunotherapy was tested in vitro and in vivo. Three computer-based algorithms were used to design eight Eps8 native epitopes with potentially high binding affinity to the HLA-A2.1 molecule, which is found at a high frequency in the Chinese population. Of these eight, three peptides with a moderate affinity to the HLA-A2.1 molecule were modified at anchor residue positions to achieve stronger immunogenicity. These four modified peptides displayed stronger binding affinity to HLA-A2.1 molecules on T2 cells and a lower dissociation rate. In functional assays with human PBMCs in vitro and in HLA-A2.1/Kb transgenic mice in vivo, CTLs primed by each native and modified peptide secreted IFN-γ and were toxic to cancer cells from a variety of tissue types in an HLA-A2.1-restricted and Eps8-specific manner. p101-09-2L and p276-84-1Y9V were superior to other modified and native epitopes both in vitro and in vivo. These results indicate that employing the native and modified epitopes identified here in Eps8-based immunotherapy for HLA-A2.1 positive cancer patients may result in efficient anticancer immune responses for diverse tumor types.